Small Cap Feast

24th November 2022

Dish of the day
No Joiners today
Off the menu
No leavers today
Dish Of The Day:
One Health Group plc (AQSE: OHGR), joins the Apex segment of the AQSE Growth Market. The group provides medical services, in the form of elective surgical care, to support the NHS in the management of patients, through a growing network of community-based outreach clinics and independent hospitals. Market Cap on admission £15.05m.
Off The Menu:
No leavers today.

What’s Cooking In The IPO Kitchen?

Kistos Holdings plc, intends to join AIM. The Company was incorporated to act as a new holding company for the group companies 0f Kistos plc (KIST), a holding company with the objective of creating value for its investors through the acquisition and management of companies or businesses in the energy sector. Anticipated Market Cap £327m. Expected 22 Dec 2022.

AT85 Global Mid-Market Infrastructure Income plc, a UK investment trust targeting an innovative, adjacent-space strategy in some of the most sought-after sectors in infrastructure, is proposing to undertake an IPO on the Premium Segment of the Main Market. The Company has access to an initial portfolio of assets of £98.5m and a total pipeline (including the Initial Assets) of £539.8m. Targeting to raise c.£300m.

Long Term Assets Limited (LTA), a Guernsey investment company, intends to join the Specialist Fund Segment of the Main Market of the London Stock Exchange. The initial portfolio is made up of a diversified range of assets, recently valued in the region of £160m, comprising a complete selection of the Disruptive Capital’s family office private asset portfolio. LTA aspires to be a “best-in-class” private assets vehicle, targeting 0.55% per annum management fee and typically a 7 to 8% p.a. hurdle rate of return. Date and amount to be raised TBD.

Life Sciences REIT plc (LABS.L), the AIM listed real estate investment trust focused on UK life science properties, announces that, in accordance with the intention expressed at the time of the Company’s initial public offering on AIM, the board has determined to apply for the Company’s existing ordinary shares to be admitted to listing on Premium Segment of the Main Market. The Company’s admission to trading on AIM will be cancelled with effect from Admission. Anticipated early December 2022.

World Chess plc, a leading chess organisation, intends to join the Main Market. World Chess Plc is the holding company of a group which aims to promote the mass market appeal of chess globally through the commercial offering of chess related activities. Euro 8m to be raised. Expected November 2022.

Breakfast Buffet

Cambridge Cognition 126.5p £39.4m (COG.L)

The developer and marketer of digital solutions to assess brain health, announces an expansion in the Chinese market through a strategic partnership with Luca Healthcare Limited, a category leader in digital screening, treatment and management tools in China. COG has signed an exclusive licencing agreement with Luca Healthcare to commercialise the Company’s suite of cognitive assessment tools in China for both the pharmaceutical and healthcare markets. COG will be paid through a mix of milestone payments and royalties. This partnership includes the opportunity to collaborate on co-developments to improve both companies’ solutions.

Cohort 430.5p £178.1m (CHRT.L)

The holding company engaged in providing services to customers in defence, security, and related markets, announces the operating segment MASS, a specialist data technology company focused on electronic warfare, digital services and training support, has been awarded a £5m contract for Electronic Warfare operational support services to an export customer. This is a 4-year extension to a contract that MASS has been undertaking for the past 15 years.

DeepMatter Group 0.06p £2.4m (DMTR.L)

The digital chemistry data and software company, announces that it has been in discussions with its major shareholders and potential institutional investors in relation to securing capital to fund the future working capital requirements. Following these discussions, the board have concluded that the cancellation of trading in the Company’s ordinary shares on AIM and subsequent re-registration as a private limited company will provide greater opportunities to raise additional capital. The Company anticipates it will seek to raise c.£1m from its major shareholders ahead of the Delisting, following which a more substantial capital raise would be pursued as a private limited company in 2023.

Global Invacom Group 7p £9.1m (GINV.L)

The global provider of satellite communications equipment and electronics, announces a trading update for the 9 months ended 30 September 2022 (Q3 FY2022). As a result of the decline in demand for satellite television products and the delay in the completion of the XRJ product, the Group expects the financial performance to be impacted in the current financial year. During this period, Global Invacom delivered revenues of approximately US$56.5m (Q3 FY2021: US$62.6m) and an EBITDA loss of approximately US$2.4m (Q3 FY2021: US$1.4m profit). The Board is conducting an operational review, with the aim of creating a more robust operational platform.

Helios Underwriting 156.5p £106.1m (HUW.L)

The investment vehicle which acquires and consolidates underwriting capacity at Lloyd’s, announces that, following the announcement released on 23 November 2022, it has raised gross proceeds of approximately £12.5m through a placing of, and a subscription for, an aggregate of 8,043,927 New Ordinary Shares at a price of £1.56 per share. The Company proposes to raise up to a further approximately £1.5m by way of a conditional open offer. The Issue Price represents a discount of approximately 0.3% to the closing price of £1.565 per share on 22 November 2022.

Hornby 28.5p £48.4m (HRN.L)

The international hobby products Group, announces its unaudited results for the six months ended 30 September 2022. Group revenue was £22.4m, a 3% increase on the prior year (2021: £21.8m). The gross margin for the period was 48% (2021: 46%), a slight increase reflecting the product/channel mix compared to prior year. Statutory loss before taxation for the period was £2.9m (2021: loss of £0.7m). Net debt was £4.9m (2021: Net cash £0.2m). Olly Raeburn had been appointed as the new CEO of Hornby, joining on 23 January 2023.

Mothercare 6.98p £39.4m (MTC.L)

The retailer announces the proposed appointment of Daniel Le Vesconte as the group’s Chief Executive Officer. Daniel will join the Board in the new calendar year. Dan brings a wealth of international brand experience in direct to consumer, franchise, wholesale and licensing, having held senior leadership roles for several globally recognised brands including Abercrombie and Fitch, Hollister and Gilly Hicks, Dr Martens, the Wolverine Worldwide group of brands and Vans and Reef.

Omega Diagnostics Group 3.65p £8.7m (ODX.L)

The specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, announces its unaudited results for the six months ended 30 September 2022. During the period the Company realigned its focus solely and strategically on the Health and Nutrition diagnostics business and disposed of loss-making CD4 business for £6.3min July 2022. Revenue decreased by 18% to £3.4m (H1 2021: £4.2m). Loss before tax was £0.7m (H1 2021: £0.0m). Cash balance was £2.7m (H1 2021: £4.7m). ODX expect a stronger H2, although full year sales will be marginally lower than previously anticipated die to the delayed US investment plans. The performance expectations of the remainder of the business remain unchanged and the Group continues to target EBITDA break even this year.

Sareum Holdings* 87.5p £59.6m (SAR.L)

The biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, announces that the Company’s Annual General Meeting will be held at 10.00 a.m. on 16 December 2022 at 100 Liverpool St, London EC2M 2AT. The AGM will also be webcast via the Investor Meet Company platform. Shareholders who wish to follow the meeting via the IMC platform should register with IMC at . A copy of the notice of AGM and the Company’s annual reports and accounts for the year ended 30 June 2022 will be available on the Company’s website

Surface Transforms 42.5p £102.2m (SCE.L)

The manufacturer of carbon fibre reinforced ceramic automotive brake discs, announces that it has been awarded a contract with a lifetime value in excess of £100m, over 6 years. As a tier one supplier of a carbon ceramic brake disc to an automotive company, it is the largest contract awarded to date. Production is expected in 2024. The Company further announces that sales for FY 22 will be lower than previously forecast at approximately £6.5m, primarily caused by technical issues at OEM 8 unrelated to its discs. The total OEM 8 contract value remains unchanged at £100m. The Company has also had its own production challenges, now materially rectified. The Company remain confident it will be profitable in 2023.

24 November 2022
*A corporate client of Hybridan LLP or retained by Hybridan LLP for certain services
** Arranged by most recent first
*** Alphabetically arranged


Our daily digest of news from UK listed Small and Mid caps straight to your Inbox.


This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email with “unsubscribe me”.

© Copyright 2024 - Hybridan | Website by Boxed Up Media
First Visit
bookcrossmenu linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram